Co-Diagnostics, Inc. – NASDAQ:CODX
Co-Diagnostics stock price today
$0.27
-0.45
-63.01%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Co-Diagnostics stock price monthly change
-45.93%
month
Co-Diagnostics stock price quarterly change
-45.93%
quarter
Co-Diagnostics stock price yearly change
-48.59%
year
Co-Diagnostics key metrics
Market Cap | 22.97M |
Enterprise value | 25.53M |
P/E | -3.33 |
EV/Sales | 0.41 |
EV/EBITDA | 10.78 |
Price/Sales | 0.77 |
Price/Book | 0.42 |
PEG ratio | 0.02 |
EPS | -1.29 |
Revenue | 6.46M |
EBITDA | -43.31M |
Income | -38.88M |
Revenue Q/Q | -58.01% |
Revenue Y/Y | -46.68% |
Profit margin | -8.41% |
Oper. margin | -34.39% |
Gross margin | 84.37% |
EBIT margin | -34.39% |
EBITDA margin | -670.28% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCo-Diagnostics stock price history
Co-Diagnostics stock forecast
Co-Diagnostics financial statements
| Jun 2023 | 197.80K | -8.91M | -4508.87% |
|---|---|---|---|
| Sep 2023 | 2.45M | -5.98M | -243.47% |
| Dec 2023 | 3.55M | -14.67M | -412.82% |
| Mar 2024 | 252.74K | -9.31M | -3684.36% |
| Dec 2023 | 3.55M | -14.67M | -412.82% |
|---|---|---|---|
| Mar 2024 | 252.74K | -9.31M | -3684.36% |
| Oct 2025 | 400K | -8.05M | -2014.39% |
| Dec 2025 | 400K | -6.86M | -1715.97% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 112801186 | 9.36M | 8.31% |
|---|---|---|---|
| Sep 2023 | 108681735 | 9.19M | 8.46% |
| Dec 2023 | 103647730 | 17.63M | 17.01% |
| Mar 2024 | 86671133 | 8.31M | 9.6% |
| Jun 2023 | -5.20M | 13.23M | -555.73K |
|---|---|---|---|
| Sep 2023 | -6.59M | 3.16M | -166.32K |
| Dec 2023 | -4.77M | 9.61M | -159.67K |
| Mar 2024 | -8.49M | 16.67M | 0 |
Co-Diagnostics alternative data
| Aug 2023 | 145 |
|---|---|
| Sep 2023 | 145 |
| Oct 2023 | 145 |
| Nov 2023 | 145 |
| Dec 2023 | 145 |
| Jan 2024 | 145 |
| Feb 2024 | 145 |
| May 2024 | 155 |
| Jun 2024 | 155 |
| Jul 2024 | 155 |
Co-Diagnostics other data
18.58%
-2.44%
of CODX is owned by hedge funds
56
-13
6.03M
-1.26M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2023 | 3000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | BROWN BRIAN LEE officer: Chief Financial Officer | Restricted Stock Unit | 134,167 | N/A | N/A | ||
Option | ABBOTT RICHARD DAVID officer: President | Restricted Stock Unit | 20,000 | N/A | N/A | ||
Option | EGAN DWIGHT H director, officer.. | Restricted Stock Unit | 163,333 | N/A | N/A | ||
Option | MURPHY TED director | Restricted Stock Unit | 48,333 | N/A | N/A | ||
Option | DURENARD EUGENE director | Restricted Stock Unit | 48,333 | N/A | N/A | ||
Option | NELSON JAMES B director | Restricted Stock Unit | 48,333 | N/A | N/A | ||
Option | SERBIN RICHARD S director | Restricted Stock Unit | 48,333 | N/A | N/A | ||
Option | BROWN BRIAN LEE officer: Chief Financial Officer | Restricted Stock Unit | 113,334 | N/A | N/A | ||
Option | EGAN DWIGHT H director, officer.. | Restricted Stock Unit | 138,333 | N/A | N/A | ||
Option | MURPHY TED director | Restricted Stock Unit | 30,000 | N/A | N/A |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 14 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Dwight H. Egan (1953) Chairman, Chief Executive Officer & Pres | $676,880 |
| Mr. Reed L. Benson (1948) Gen. Counsel | $453,960 |
-
What's the price of Co-Diagnostics stock today?
One share of Co-Diagnostics stock can currently be purchased for approximately $0.27.
-
When is Co-Diagnostics's next earnings date?
Unfortunately, Co-Diagnostics's (CODX) next earnings date is currently unknown.
-
Does Co-Diagnostics pay dividends?
No, Co-Diagnostics does not pay dividends.
-
How much money does Co-Diagnostics make?
Co-Diagnostics has a market capitalization of 22.97M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 80.09% to 6.81M US dollars.
-
What is Co-Diagnostics's stock symbol?
Co-Diagnostics, Inc. is traded on the NASDAQ under the ticker symbol "CODX".
-
What is Co-Diagnostics's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of Co-Diagnostics?
Shares of Co-Diagnostics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Co-Diagnostics's key executives?
Co-Diagnostics's management team includes the following people:
- Mr. Dwight H. Egan Chairman, Chief Executive Officer & Pres(age: 72, pay: $676,880)
- Mr. Reed L. Benson Gen. Counsel(age: 77, pay: $453,960)
-
How many employees does Co-Diagnostics have?
As Jul 2024, Co-Diagnostics employs 155 workers, which is 7% more then previous quarter.
-
When Co-Diagnostics went public?
Co-Diagnostics, Inc. is publicly traded company for more then 8 years since IPO on 12 Jul 2017.
-
What is Co-Diagnostics's official website?
The official website for Co-Diagnostics is codiagnostics.com.
-
Where are Co-Diagnostics's headquarters?
Co-Diagnostics is headquartered at 2401 South Foothill Drive, Salt Lake City, UT.
-
How can i contact Co-Diagnostics?
Co-Diagnostics's mailing address is 2401 South Foothill Drive, Salt Lake City, UT and company can be reached via phone at 801 438 1036.
Co-Diagnostics company profile:
Co-Diagnostics, Inc.
codiagnostics.comExchange:
NASDAQ
Full time employees:
155
Industry:
Medical - Devices
Sector:
Healthcare
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
2401 South Foothill Drive
Salt Lake City, UT 84109
Salt Lake City, UT 84109
CIK: 0001692415
ISIN: US1897631057
CUSIP: 189763105
